Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Current Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Current Leases for 5 consecutive years, with $85210.0 as the latest value for Q3 2025.

  • Quarterly Current Leases fell 34.39% to $85210.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $85210.0 through Sep 2025, down 34.39% year-over-year, with the annual reading at $116314.0 for FY2025, N/A changed from the prior year.
  • Current Leases for Q3 2025 was $85210.0 at Neuphoria Therapeutics, down from $116314.0 in the prior quarter.
  • The five-year high for Current Leases was $129881.0 in Q3 2024, with the low at $85210.0 in Q3 2025.
  • Average Current Leases over 4 years is $114445.5, with a median of $116314.0 recorded in 2025.
  • The sharpest move saw Current Leases rose 0.19% in 2023, then tumbled 34.39% in 2025.
  • Over 4 years, Current Leases stood at $114631.6 in 2022, then grew by 0.19% to $114851.7 in 2023, then grew by 3.17% to $118492.0 in 2024, then dropped by 28.09% to $85210.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $85210.0, $116314.0, and $121738.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.